RSV vaccines for Pregnant Women and Newborns

Dr. Sherri Tenpenny

August 4, 2023

Last week I posted a substack on the newly approved RSV vaccines for adults. If you missed it, you can find it here. A few additional notes about RSV vaccines for adults:

  1. March 2023 – Johnson and Johnson (J&J) stopped its phase III clinical trials for its RSV vaccine.
  2. May 2023 – GlaxoSmithKline (GSK) last year stopped a late-stage clinical trial of its RSV vaccine in pregnant women due to an elevated risk of premature birth and associated neonatal deaths in the babies born prematurely. In the GSK trial, premature birth was 38% more likely in the vaccinated pregnancies than in the placebo group.
  3. July 2023 – Bavarian Nordic ends RSV vaccine program after poor trial results, only demonstrating a 42.9% efficacy for preventing severe lower respiratory tract illness. Ending the program means the company will no longer be eligible for 195 million kroner ($28.9 million) in milestone payments from its Chinese partner, Nuance Pharma, which had planned to launch the RSV vaccine into Asian markets this fall.

This week, Eye on the Evidence is taking a look at the new RSV vaccines that will target newborns, toddlers, and pregnant women.

Read More HERE